Department of Cardiology and Angiology II, Medical Center, University of Freiburg, University Heart Center Freiburg-Bad Krozingen, Suedring 15, 79189, Bad Krozingen, Germany.
Cantonal Hospital Baselland, Liestal, Switzerland.
J Thromb Thrombolysis. 2022 Jan;53(1):1-9. doi: 10.1007/s11239-021-02515-2. Epub 2021 Jul 2.
Lipoprotein(a) [Lp(a)] is an independent, genetically determined, and causal risk factor for cardiovascular disease. Laboratory data have suggested an interaction of Lp(a) with platelet function, potentially caused by its interaction with platelet receptors. So far, the potential association of Lp(a) with platelet activation and reactivity has not been proven in larger clinical cohorts. This study analyzed intrinsic platelet reactivity before loading with clopidogrel 600 mg and on-treatment platelet reactivity tested 24 h following loading in patients undergoing elective coronary angiography. Platelet reactivity was tested by optical aggregometry following stimulation with collagen or adenosine diphosphate as well as by flow cytometry. Lp(a) levels were directly measured in all patients from fresh samples. The present analysis included 1912 patients. Lp(a) levels ranged between 0 and 332 mg/dl. There was a significant association of rising levels of Lp(a) with a higher prevalence of a history of ischemic heart disease (p < 0.001) and more extensive coronary artery disease (p = 0.001). Results for intrinsic (p = 0.80) and on-clopidogrel platelet reactivity (p = 0.81) did not differ between quartiles of Lp(a) levels. Flow cytometry analyses of expression of different platelet surface proteins (CD41, CD62P or PAC-1) confirmed these findings. Correlation analyses of levels of Lp(a) with any of the tested platelet activation markers did not show any correlation. The present data do not support the hypothesis of an interaction of Lp(a) with platelet reactivity.
脂蛋白(a)[Lp(a)]是心血管疾病的独立、遗传决定和因果风险因素。实验室数据表明,Lp(a)与血小板功能相互作用,这可能是由于其与血小板受体相互作用所致。迄今为止,尚未在更大的临床队列中证明 Lp(a)与血小板激活和反应性之间的潜在关联。本研究分析了在接受选择性冠状动脉造影的患者中,在服用氯吡格雷 600mg 前测定的血小板固有反应性和服用氯吡格雷 24 小时后的血小板反应性。通过光学聚集法在胶原或二磷酸腺苷刺激下以及通过流式细胞术测定血小板反应性。所有患者均从新鲜样本中直接测量 Lp(a)水平。本分析包括 1912 例患者。Lp(a)水平在 0 至 332mg/dl 之间。Lp(a)水平升高与缺血性心脏病史(p<0.001)和更广泛的冠状动脉疾病(p=0.001)的患病率升高呈显著相关。固有(p=0.80)和氯吡格雷后血小板反应性(p=0.81)的结果在 Lp(a)水平四分位数之间没有差异。不同血小板表面蛋白(CD41、CD62P 或 PAC-1)表达的流式细胞术分析证实了这些发现。Lp(a)水平与任何测试的血小板激活标志物之间的相关性分析未显示出任何相关性。本数据不支持 Lp(a)与血小板反应性相互作用的假设。